{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.ai-analytics.org/api/v1/entity/CHRS/timeline","_source":{"data_provider":"AI Analytics","data_provider_url":"https://api.ai-analytics.org","license":"https://api.ai-analytics.org/license","usage_info":"https://api.ai-analytics.org/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-09-23T01:26:39.170Z","methodology_url":"https://api.ai-analytics.org/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":3021,"canonical_name":"Coherus Oncology, Inc.","cik":"0001512762","uei":null,"lei":null,"duns":null,"ticker":"CHRS"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","open.payments","dol.form5500","hud.housing","irs.bmf"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"fda":1,"sec":22,"clinical":1},"count":24,"timeline":[{"ts":"20260105","kind":"fda.label","reporter":"Coherus Oncology, Inc.","title":"LOQTORZI","security_title":"TORIPALIMAB-TPZI","excerpt":"1 INDICATIONS AND USAGE LOQTORZI is a programmed death receptor-1 (PD-1)- blocking antibody indicated: in combination with cisplatin and gemcitabine, for first-line treatment of adults with metastatic","accession_number":"82e7921a-1e84-4988-9799-0ad7d19b2a75","route":"INTRAVENOUS","product_type":"HUMAN PRESCRIPTION DRUG","importance":30},{"ts":"2026-06-15","kind":"sec.filing","form_type":"8-K","title":"8-K — Coherus Oncology, Inc. — 2026-06-15","url_slug":"/sec/cik-0001512762/8-k/0001104659-26-074090","accession_number":"0001104659-26-074090","importance":35},{"ts":"2026-06-09","kind":"sec.filing","form_type":"4","title":"4 — Coherus Oncology, Inc. — 2026-06-09","url_slug":"/sec/cik-0001512762/4/0001610717-26-000200","accession_number":"0001610717-26-000200","importance":30},{"ts":"2026-06-09","kind":"sec.filing","form_type":"4","title":"4 — Coherus Oncology, Inc. — 2026-06-09","url_slug":"/sec/cik-0001512762/4/0001610717-26-000202","accession_number":"0001610717-26-000202","importance":30},{"ts":"2026-06-09","kind":"sec.filing","form_type":"4","title":"4 — Coherus Oncology, Inc. — 2026-06-09","url_slug":"/sec/cik-0001512762/4/0001610717-26-000203","accession_number":"0001610717-26-000203","importance":30},{"ts":"2026-06-09","kind":"sec.filing","form_type":"4","title":"4 — Coherus Oncology, Inc. — 2026-06-09","url_slug":"/sec/cik-0001512762/4/0001610717-26-000204","accession_number":"0001610717-26-000204","importance":30},{"ts":"2026-06-09","kind":"sec.filing","form_type":"4","title":"4 — Coherus Oncology, Inc. — 2026-06-09","url_slug":"/sec/cik-0001512762/4/0001610717-26-000205","accession_number":"0001610717-26-000205","importance":30},{"ts":"2026-06-09","kind":"sec.filing","form_type":"4","title":"4 — Coherus Oncology, Inc. — 2026-06-09","url_slug":"/sec/cik-0001512762/4/0001610717-26-000206","accession_number":"0001610717-26-000206","importance":30},{"ts":"2026-06-05","kind":"sec.insider.30000","reporter":"Satvat Ali J.","title":null,"shares":30000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-05","kind":"sec.insider.a","reporter":"Wahlstrom Mats","title":null,"shares":30000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-05","kind":"sec.insider.a","reporter":"O'Donnell-Tormey Jill","title":null,"shares":30000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-05","kind":"sec.insider.a","reporter":"Newton Charles W.","title":null,"shares":30000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-05","kind":"sec.insider.a","reporter":"Ryan Michael Lee","title":null,"shares":30000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-05","kind":"sec.insider.a","reporter":"Newcomer Lee Nisley","title":null,"shares":30000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-05","kind":"sec.insider.a","reporter":"Satvat Ali J.","title":null,"shares":30000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-05","kind":"sec.insider.a","reporter":"Karachun Rita A","title":null,"shares":30000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-02","kind":"sec.filing","form_type":"4","title":"4 — Coherus Oncology, Inc. — 2026-06-02","url_slug":"/sec/cik-0001512762/4/0001104659-26-069622","accession_number":"0001104659-26-069622","importance":30},{"ts":"2026-06-01","kind":"sec.filing","form_type":"8-K","title":"8-K — Coherus Oncology, Inc. — 2026-06-01","url_slug":"/sec/cik-0001512762/8-k/0001104659-26-068615","accession_number":"0001104659-26-068615","importance":35},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Coherus Oncology, Inc. — 2026-05-15","url_slug":"/sec/cik-0001512762/schedule-13g-a/0002109159-26-000003","accession_number":"0002109159-26-000003","importance":30},{"ts":"2026-05-11","kind":"sec.13dg","reporter":"Coherus Oncology, Inc.","shares":null,"percent_of_class":null,"security_title":"SCHEDULE 13G/A","accession_number":"0002109159-26-000002","excerpt":null,"importance":55},{"ts":"2026-05-11","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Coherus Oncology, Inc. — 2026-05-11","url_slug":"/sec/cik-0001512762/10-q/0001104659-26-058703","accession_number":"0001104659-26-058703","importance":45},{"ts":"2026-05-11","kind":"sec.filing","form_type":"8-K","title":"8-K — Coherus Oncology, Inc. — 2026-05-11","url_slug":"/sec/cik-0001512762/8-k/0001104659-26-058666","accession_number":"0001104659-26-058666","importance":35},{"ts":"2026-05-11","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Coherus Oncology, Inc. — 2026-05-11","url_slug":"/sec/cik-0001512762/schedule-13g-a/0002109159-26-000002","accession_number":"0002109159-26-000002","importance":30},{"ts":"2026-04-06","kind":"clinical.trial","reporter":"Coherus Oncology, Inc.","title":"A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer","security_title":"PHASE4","status":"RECRUITING","accession_number":"NCT06457503","excerpt":"[\"Nasopharyngeal Cancer Recurrent\"]","importance":25}]}